Healthcare Industry News: Baxter International
News Release - May 22, 2008
CyDex Pharmaceuticals Appoints Theron (Ted) Odlaug, Ph.D. as President and Chief Operating OfficerLENEXA, Kan.--(HSMN NewsFeed)--CyDex Pharmaceuticals, Inc. today announced that Theron (Ted) E. Odlaug, Ph.D. has been appointed to the newly established position of president and chief operating officer.
Dr. Odlaug’s 30 years of experience includes senior leadership roles with Astellas, Fujisawa, Bayer AG and Baxter International and spans a broad range of regulatory and commercialization processes in the pharmaceutical and life science fields.
“We are pleased to welcome a person with Ted Odlaug’s vision, industry knowledge and record of outstanding leadership to the CyDex management team,” said John M. Siebert, Ph.D., chairman and chief executive officer. “Ted’s experience in leading and growing pharmaceutical organizations will add significant value to CyDex and our management team.”
Dr. Odlaug served as executive vice president and a member of the senior management committee at Fujisawa Healthcare Inc. until its merger with Yamanouchi in 2005, which resulted in the formation of Astellas Pharma. He left Astellas in 2006 after successfully completing the post-merger integration process, and most recently was the managing partner of EIR Healthcare Advisors, LLC. While at Fujisawa, Dr. Odlaug was responsible for manufacturing, regulatory and quality assurance, technical services, commercial compliance, human resources, legal, information technology, corporate communications and strategic relations.
Dr. Odlaug serves on the board of publicly held Advanced Life Sciences Holdings, Inc., where he is a member of the compensation committee and nominating and governance committee. He also has been a member of the board of the privately held Wahl Clipper Corporation and a member of its compensation committee. He holds Bachelor’s and Master’s degrees from the University of Missouri at Kansas City and a Ph.D. in Public Health from the University of Minnesota.
About CyDex Pharmaceuticals
CyDex Pharmaceuticals, Inc. is a specialty pharmaceutical company developing products and licensing its CAPTISOL® enabling technology. CyDex is developing its own pipeline of products using its enabling technology solutions, and partnering with leading pharmaceutical, specialty pharmaceutical and biotechnology companies. CyDex is a privately held company located in suburban Kansas City. To learn more about the company, please visit www.cydexpharma.com.
Source: Cydex Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.